Product
ACE-536
Aliases
BMS-986346, Luspatercept
Name
Reblozyl
INN Name
Luspatercept
FDA Approved
Yes
2 clinical trials
1 organization
6 indications
1 document
Indication
Myeloproliferative DisordersIndication
MyelofibrosisIndication
Primary MyelofibrosisIndication
Post-Polycythemia Vera MyelofibrosisIndication
AnaemiaIndication
Beta ThalassemiaClinical trial
A Phase 3, Double-blind, Randomized Study to Compare the Efficacy and Safety of Luspatercept (ACE-536) Versus Placebo in Subjects With Myeloproliferative Neoplasm-Associated Myelofibrosis on Concomitant JAK Inhibitor Therapy and Who Require Red Blood Cell TransfusionsStatus: Recruiting, Estimated PCD: 2025-03-27
Clinical trial
A Phase 2a Study to Evaluate the Safety and Pharmacokinetics of Luspatercept (ACE-536) in Pediatric Participants With Beta (β)-ThalassemiaStatus: Recruiting, Estimated PCD: 2026-06-30
Document
DailyMed Label: ReblozylOrganization
Celgene Corporation